MindBio Therapeutics Corp.
MBIO
CNSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -25.37% | 1,546.73% | |||
| Depreciation & Amortization | 100.35% | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.25% | 1,456.14% | |||
| Operating Income | 19.25% | -1,456.14% | |||
| Income Before Tax | 14.07% | -55.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 14.07% | -55.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 90.91% | -512.50% | |||
| Net Income | 14.33% | -56.14% | |||
| EBIT | 19.25% | -1,456.14% | |||
| EBITDA | 19.27% | -1,456.14% | |||
| EPS Basic | 99.74% | 49.64% | |||
| Normalized Basic EPS | 99.81% | -305.75% | |||
| EPS Diluted | 99.74% | 49.64% | |||
| Normalized Diluted EPS | 99.81% | -305.75% | |||
| Average Basic Shares Outstanding | 32,822.73% | 210.02% | |||
| Average Diluted Shares Outstanding | 32,822.73% | 210.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||